^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    IL18BP (Interleukin 18 Binding Protein)

    i
    Other names: IL18BP, Interleukin 18 Binding Protein, MC51L-53L-54L Homolog Gene Product, Interleukin-18-Binding Protein, Tadekinig-Alfa, IL18BPa, IL-18BP
    27d
    Liver metastases dampen IL18-driven γδ T cell activity and immunotherapy responsiveness in colorectal cancer. (PubMed, Cell Rep Med)
    Blockade of IL18BP enhances interferon (IFN) γ-driven immunity against organoids in vitro. Taken together, we identify the IL18/IL18BP/Vδ1+ axis as an important regulator of ICB response and a therapeutic vulnerability for patients with LMs of MMR-d tumors.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • IL18 (Interleukin 18) • IL18BP (Interleukin 18 Binding Protein)
    |
    MSI-H/dMMR
    2ms
    Targeting highly attenuated IL-18 to PD-1 for enhanced anti-tumor activity. (PubMed, Front Immunol)
    It increased CD8+ progenitor-exhausted tumor-infiltrating lymphocytes (TILs) while reducing myeloid TILs. Attaching a highly attenuated IL-18 to an anti-PD-1 antibody goes beyond simply targeting a cytokine to PD-1, representing a novel cytokine-enhanced checkpoint inhibitor that activates PD-1+ T cells via the cytokine receptor while simultaneously antagonizing PD-1.
    Journal
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL18 (Interleukin 18) • IL18BP (Interleukin 18 Binding Protein)
    2ms
    Interleukin-18 binding protein deficiency results in gut microbiota dysbiosis and aggravated diet-induced MASH in mice. (PubMed, JHEP Rep)
    We presently highlight a previously unknown protective role of IL-18BP in the integrity of the gut-liver axis. Increasing IL-18-binding protein levels (a clinically validated option to treat rare systemic auto-inflammatory diseases) represents a novel therapeutic perspective, not only for patients with MASLD/MASH, but also for patients presenting gut microbiota dysbiosis.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL18 (Interleukin 18) • IL18BP (Interleukin 18 Binding Protein)
    6ms
    Epstein-Barr Virus Seropositivity, Immune Dysregulation, and Mortality in Pediatric Sepsis. (PubMed, JAMA Netw Open)
    In this cohort study of pediatric sepsis, EBV seropositivity was associated with immune dysregulation and mortality. Further study is warranted to address the possibility that latent EBV infection immune reprogramming poses an important public health problem that contributes to not only chronic disorders of immune dysregulation but also acute disorders of immune dysregulation, such as sepsis.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL18 (Interleukin 18) • IL18BP (Interleukin 18 Binding Protein) • CRP (C-reactive protein)
    8ms
    Effects of allergens on the expression levels of interleukin 18, interleukin 18 binding protein a and interleukin 18 receptor α in the blood monocyte subtypes of patients with allergic asthma (PubMed, Zhonghua Nei Ke Za Zhi)
    Allergens may participate in the inflammatory response of AA by inducing the differentiation of monocytes and the expression levels of IL-18, IL-18BPa and IL-18Rα in different blood monocytes subtypes. Classical monocytes are the potential source of elevated plasma IL-18 level in AA patients.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL18 (Interleukin 18) • IL18BP (Interleukin 18 Binding Protein) • IL1B (Interleukin 1, beta)
    1year
    Subtype-associated complexity and prognostic significance of the NLRP3 inflammasome landscape in pancreatic neoplasms. (PubMed, J Pathol Clin Res)
    Our findings highlight the prognostic significance of IL-18 and the IL-18/IL-18BP ratio in invasive IPMNs. These results point to a complex regulation of NLRP3 inflammasome proteins, especially effector cytokines, in pancreatic neoplasms, which are strongly linked to subtype and prognosis.
    Journal
    |
    IL18 (Interleukin 18) • NLRC5 (NLR Family CARD Domain Containing 5) • IL18BP (Interleukin 18 Binding Protein) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    1year
    Exploring the role of circulating proteins in multiple myeloma risk: a Mendelian randomization study. (PubMed, Sci Rep)
    Although evidence from genetic colocalization suggests these associations may not be robust to the effects of horizontal pleiotropy, these proteins may be useful markers of MM risk. Future work should explore the utility of these proteins in disease prediction or prevention using proteomic data from patients with MM or precursor conditions.
    Journal
    |
    KDR (Kinase insert domain receptor) • IL18BP (Interleukin 18 Binding Protein)
    1year
    Combined delivery of IL12 and an IL18 mutant without IL18BP-binding activity by an adenoviral vector enhances tumor specific immunity. (PubMed, Sci Rep)
    Importantly, mice that had tumor regression after oAd.DR18/IL12 treatment established anti-tumor specific immune memory. These results show that adenovirus armed with engineered cytokines boosts tumor specific immunity and antitumor effect.
    Journal
    |
    IFNG (Interferon, gamma) • IL18BP (Interleukin 18 Binding Protein)
    1year
    Computational modeling of the anti-inflammatory complexes of IL37. (PubMed, J Mol Graph Model)
    Further, investigations into interactions between IL37 and IL18BP suggested that a binding mode homologous to IL18 was unstable for IL37, indicating an alternative binding mechanism. Altogether, this study accesses to the structure and dynamics of IL37 complexes, revealing the structural underpinnings of the IL37's modulatory effect on the IL18 signaling pathway.
    Journal
    |
    IL18BP (Interleukin 18 Binding Protein)
    over1year
    Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma. (PubMed, JCI Insight)
    This activity correlated with intra-tumoral enrichment and clonal expansion of effector CD8+ T cells, decreased regulatory T cell levels, and enrichment of pro-inflammatory, anti-tumor myeloid cell populations. Our findings support further clinical investigation of the combination of DR-18 and anti-CTLA-4 in RCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IL18 (Interleukin 18) • IL18BP (Interleukin 18 Binding Protein)
    over1year
    Transcriptome analysis of the cytokine storm-related genes among the subtypes of idiopathic multicentric Castleman disease. (PubMed, J Clin Exp Hematop)
    Particularly, upregulated IL33 expression was demonstrated for the first time in iMCD-TAFRO/NOS. Thus, inflammatory signaling, such as JAK-STAT and MAPK, may be enhanced in iMCD-TAFRO/NOS and may be a cytokine storm.
    Journal
    |
    JAK2 (Janus kinase 2) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • JAK1 (Janus Kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • MAPK1 (Mitogen-activated protein kinase 1) • VEGFC (Vascular Endothelial Growth Factor C) • IL17A (Interleukin 17A) • IL17RA (Interleukin 17 Receptor A) • PDGFA (Platelet Derived Growth Factor Subunit A) • PDGFB (Platelet Derived Growth Factor Subunit B) • STAT1 (Signal Transducer And Activator Of Transcription 1) • STAT6 (Signal transducer and activator of transcription 6) • IL18BP (Interleukin 18 Binding Protein) • IL1R1 (Interleukin 1 receptor, type I) • IL1RAP (Interleukin 1 Receptor Accessory Protein) • NFKBIA (NFKB Inhibitor Alpha 2) • STAT2 (Signal transducer and activator of transcription 2) • IL3 (Interleukin 3) • IL33 (Interleukin 33) • MAPK11 (Mitogen-Activated Protein Kinase 11) • MAPK12 (Mitogen-Activated Protein Kinase 12) • MAPK14 (Mitogen-Activated Protein Kinase 14) • MAPK3 (Mitogen-Activated Protein Kinase 3) • MAPK8 (Mitogen-activated protein kinase 8) • MAPK9 (Mitogen-Activated Protein Kinase 9) • PDGFC (Platelet Derived Growth Factor C) • TNFAIP8 (TNF Alpha Induced Protein 8) • MAPK10 (Mitogen-Activated Protein Kinase 10)
    over1year
    Analysis of the role of IL-1 family and related genes in head and neck squamous cell carcinoma. (PubMed, Braz J Otorhinolaryngol)
    The differential expression of the IL-1 family and related genes affects the microenvironment changes and survival prognosis of HNSCC patients. Among them, IL-1α, IL1RAP, IL18RAP, and SIGIRR may affect the prognosis of patients by affecting local CD8+ T cell infiltration in the tumor.
    Journal
    |
    CD8 (cluster of differentiation 8) • IL18BP (Interleukin 18 Binding Protein) • IL1B (Interleukin 1, beta) • IL1R1 (Interleukin 1 receptor, type I) • IL1RAP (Interleukin 1 Receptor Accessory Protein) • IL1RN (Interleukin 1 receptor antagonist) • IL1F10 (Interleukin 1 Family Member 10) • IL33 (Interleukin 33) • CASP1 (Caspase 1)
    |
    CXCL8 expression